Novo Nordisk's India Price Cuts Amplify Global Competitive Fears Amid U.S. Turmoil

What happened

Novo Nordisk slashed prices on Wegovy and Ozempic by up to 48% in India in early April 2026, a direct response to low-cost generic semaglutide flooding that market. This action mirrors the 'unprecedented pricing pressure' highlighted in Novo's 2026 guidance, as per the DeepValue report, which frames the company's struggle against Eli Lilly's share gains and PBM-driven rebates in the U.S. The report's investment thesis hinges on near-term U.S. supports like a $4.2 billion 340B revenue recognition in Q1 2026 and Medicare expansion in July, arguing that current valuation prices in a profit-pool collapse. However, India's price cuts suggest generic competition is spreading beyond the U.S., potentially undermining international margins that the report largely sidelines. Despite this, the DeepValue analysis maintains a 'POTENTIAL BUY' rating, contingent on U.S. prescription trends stabilizing after recent product launches.

Implication

The India price cuts reveal that generic competition is accelerating in key emerging markets, adding a new layer of margin pressure beyond the U.S.-focused narrative. This aligns with the DeepValue report's bear scenario, where broader price resets force permanent margin compression, increasing the probability of that outcome. While the report's base case relies on U.S. dynamics like the 340B revenue tailwind, international headwinds could offset these benefits if similar cuts spread to other regions. Monitoring ex-U.S. pricing trends becomes crucial, as sustained erosion there would challenge earnings durability even if U.S. prescriptions stabilize. Consequently, investors should temper optimism from near-term catalysts with heightened scrutiny on global competitive intensity.

Thesis delta

The India price cuts do not shift the core DeepValue thesis, which remains anchored to U.S. market dynamics and accounting tailwinds. However, they reinforce the downside risk that competitive pressures are more geographically widespread, potentially necessitating a reassessment of international revenue assumptions if generic incursions intensify. This news slightly tilts the risk-reward balance toward the bear case, urging caution without altering the fundamental buy rationale based on U.S. stabilization prospects.